<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03618472</url>
  </required_header>
  <id_info>
    <org_study_id>Rjmetformin</org_study_id>
    <nct_id>NCT03618472</nct_id>
  </id_info>
  <brief_title>Comparison of the Effectiveness Metformin for Deceasing Proliferative Marker in Endometrial Cancer Cells</brief_title>
  <official_title>Effect of Metformin for Deceasing Proliferative Marker in Endometrial Cancer Cells : A Randomized Double Blind Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rajavithi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rajavithi Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of the effectiveness metformin versus placebo for deceasing proliferative marker
      Ki-67 expression in endometrial tumours when given for 4 weeks before hysterectomy in
      endometrial cancer cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endometrial cancer is one of the most common gynecological cancers. Preclinical studies in
      endometrial cancer (EC) show that metformin reduces cellular proliferation by PI3K-AKT-mTOR
      inhibition. The investigators tested the hypothesis that short-term presurgical metformin
      reduces cellular proliferation in endometrial cancer. However, no good quality of evidence
      base supports the effectiveness of metformin for deceasing proliferative marker in
      endometrial cancer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Actual">January 7, 2020</completion_date>
  <primary_completion_date type="Actual">November 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Ki-67 expression in endometrial tumor</measure>
    <time_frame>4 weeks</time_frame>
    <description>metformin administration reduced Ki-67 expression in endometrial tumor when given for 4 weeks before hysterectomy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of grade in endometrial tumor</measure>
    <time_frame>4 weeks</time_frame>
    <description>metformin administration reduced grade in endometrial tumor when given for 4 weeks before hysterectomy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Metformin</condition>
  <condition>CA Endometrium</condition>
  <arm_group>
    <arm_group_label>metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participant will be eat metformin 850 mg 1 tab daily,4 weeks prior to hysterectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The participant will be eat placebo (same shape, size, color)1 tab daily ,4 weeks prior to hysterectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Hydrochloride 850 MG</intervention_name>
    <description>Regular strength metformin (850 mg/tab)</description>
    <arm_group_label>metformin</arm_group_label>
    <other_name>if any</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Starch based placebo manufatured to mimic Metformin 850 mg</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>if any</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with endometrial cancer who undergoing complete surgical staging and agrees to
             participate in this study

        Exclusion Criteria:

          -  Women without diabetes type 1 and 2

          -  Women who have allergy Biguanide

          -  Women who have hypoglycemic medication

          -  Women who have GFR &lt;45 ml/min/1.73 m2

          -  Women who have evidence of stage 3 or 4 of endometrial cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rajavithi Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>August 1, 2018</study_first_submitted>
  <study_first_submitted_qc>August 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2018</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

